Bayer slides on €9.5bn loss caused by litigation, COVID-19 impactBayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion Share XBayer slides on €9.5bn loss caused by litigation, COVID-19 impacthttps://pharmaphorum.com/news/bayer-slides-on-e9-5bn-loss-caused-by-litigation-covid-19-impact/
BI opens second branch of digital lab in ChinaBoehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in Share XBI opens second branch of digital lab in Chinahttps://pharmaphorum.com/news/bi-opens-branch-of-digital-lab-in-china/
Does pharma’s future lie in China?Healthcare innovation has a long history in effective collaboration, whether that’s across academia and industry or borders. Some Share XDoes pharma’s future lie in China?https://pharmaphorum.com/r-d/views-analysis-r-d/does-pharmas-future-lie-in-china/
Vifor forges iron drug partnership with Fresenius in ChinaVifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency Share XVifor forges iron drug partnership with Fresenius in Chinahttps://pharmaphorum.com/news/vifor-forges-iron-drug-partnership-with-fresenius-in-china/
Nine pharma trends for 2020Sarah Rickwood looks back at how pharma changed over the last decade and what this might mean for Share XNine pharma trends for 2020https://pharmaphorum.com/views-analysis-digital/nine-pharma-trends-for-2020/
China’s Adagene raises $69m for cancer immunotherapiesChinese biotech Adagene has raised $69 million in fourth-round financing to help usher its immuno-oncology drugs – including Share XChina’s Adagene raises $69m for cancer immunotherapieshttps://pharmaphorum.com/news/chinas-adagene-raises-69m-for-cancer-immunotherapies/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Geopolitical uncertainty grips digital health investorsGalen Growth Asia has released its Q3 2019 Asia Pac HealthTech, aka digital health, ecosystem key trends interim Share XGeopolitical uncertainty grips digital health investorshttps://pharmaphorum.com/views-analysis-digital/geopolitical-uncertainty-grips-digital-health-investors/
Amgen pays $2.7bn to harness BeiGene’s China marketing muscleFuelled by sweeping regulatory reforms and a massive ageing population, China is a key market for most big Share XAmgen pays $2.7bn to harness BeiGene’s China marketing musclehttps://pharmaphorum.com/news/amgen-pays-2-7bn-to-harness-beigenes-china-marketing-muscle/
